ABIOMED (NASDAQ:ABMD) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.
A number of other analysts have also recently weighed in on ABMD. SunTrust Banks started coverage on shares of ABIOMED in a report on Friday, September 29th. They issued a “buy” rating and a $195.00 price objective on the stock. Jefferies Group increased their price objective on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of ABIOMED in a report on Thursday, January 4th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 price objective on the stock in a report on Friday, December 29th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. ABIOMED presently has a consensus rating of “Buy” and a consensus price target of $210.50.
Shares of ABIOMED (ABMD) opened at $228.29 on Friday. The firm has a market cap of $10,090.00, a price-to-earnings ratio of 112.46, a price-to-earnings-growth ratio of 2.96 and a beta of 0.15. ABIOMED has a twelve month low of $103.53 and a twelve month high of $229.05. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02.
ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.16. The company had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The firm’s revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 earnings per share. sell-side analysts anticipate that ABIOMED will post 2.41 EPS for the current fiscal year.
In related news, Director Dorothy E. Puhy sold 6,364 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael G. Howley sold 10,000 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue bought a new position in ABIOMED in the 4th quarter valued at about $562,000. Fox Run Management L.L.C. bought a new position in ABIOMED in the 4th quarter valued at about $315,000. Hamilton Lane Advisors LLC grew its position in ABIOMED by 50.8% in the 4th quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock valued at $4,356,000 after buying an additional 7,827 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in ABIOMED by 7.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 137,552 shares of the medical equipment provider’s stock valued at $25,779,000 after buying an additional 9,370 shares in the last quarter. Finally, Creative Planning grew its position in ABIOMED by 50.1% in the 4th quarter. Creative Planning now owns 6,033 shares of the medical equipment provider’s stock valued at $1,131,000 after buying an additional 2,015 shares in the last quarter. Hedge funds and other institutional investors own 90.75% of the company’s stock.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.